“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial of selumetinib with chemotherapy for advanced biliary tract cancers (ABC 04)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a drug called selumetinib with chemotherapy for cancer of the bile duct or gallbladder (the biliary tract). Cancer Research UK supported this trial.
More about this trial
- it can’t be removed by surgery
- it comes back after surgery
- it spreads to another part of the body
Selumetinib is a type of biological therapy called a
The aims of this study were to
- find the best dose of selumetinib to have with chemotherapy for advanced biliary tract cancer
- learn more about the side effects
Summary of results
The team found the best dose of selumetinib to give with cisplatin and gemcitabine for biliary tract cancers.
This was a phase 1 trial.
At the start 3 people had 75mg of selumetinib with their chemotherapy. As they didn’t have any serious side effects another 3 people were started on this dose. This continued until 12 people had this dose of selumetinib with chemotherapy.
Of the 12 people only 1 person had a side effect serious enough to stop selumetinib or reduce the dose. The side effect was chest pain.
Other side effects included
- a drop in blood cells causing an increased risk of infection, bruising and bleeding
- feeling or being sick
- constipation or diarrhoea
- a change to how the liver works
The trial team concluded that 75mg of selumetinib twice a day was the best dose to give.
Other studies are now being done. These are to find substances in the body (biomarkers) that could be used to predict how well people might respond to this combination of treatment.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr John Bridgewater
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)
This is Cancer Research UK trial number CRUKE/10/036